id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
8313300_7 | Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"because\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"polyuria\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
7594371_2 | Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"sensorineural hearing loss\"]], \"start\": [[72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"PAN and methotrexate\"]], \"start\": [[5]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"PAN\"], [\"methotrexate\"]], \"start\": [[5], [13]], \"entity_id\": [\"T8\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"PAN\"], [\"methotrexate\"]], \"start\": [[5], [13]], \"entity_id\": [\"T8\", \"T10\"]}}]}}"
}
]
}
] |
19667003_14 | CONCLUSION: A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 26-year-old man with bipolar disorder\"]], \"start\": [[12]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"26-year-old\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hyperammonemia\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"three weeks after initiating carbamazepine therapy\"]], \"start\": [[77]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"three weeks\"]], \"start\": [[77]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[106]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"bipolar disorder\"]], \"start\": [[35]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
11034877_2 | We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"gabapentin (GBP)\"]], \"start\": [[34]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gabapentin\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"behavioural side effects\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"two adults\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}, \"Age\": {\"text\": [[\"adults\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
4038927_1 | Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diltiazem\"]], \"start\": [[35]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"diltiazem\"]], \"start\": [[35]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[48]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Atrial fibrillation\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[75]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"verapamil\"]], \"start\": [[65]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[65]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"syncope\"]], \"start\": [[83]], \"entity_id\": [\"T17\"]}, \"Subject\": {\"text\": [[\"one patient\"]], \"start\": [[94]], \"entity_id\": [\"T12\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[94]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
21448111_6 | We can conclude that in this case, as in many others, akathisia as a possible adverse effect of psychopharmacs was very hard to identify. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effect\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"psychopharmacs\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"psychopharmacs\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"akathisia\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"this case\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
18176653_12 | Although HAART is very important in the treatment of HIV, its side effects are responsible for patients' non-adherence to medications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"HAART\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"HAART\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"non-adherence to medications\"]], \"start\": [[105]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[95]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
7668127_2 | A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[147]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"acute subdural haematoma\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an angiomatous meningioma in a patient\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[128]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[128]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16529136_4 | Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitate\"]], \"start\": [[178]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"monoamine oxidase inhibitors (MAOIs)\"]], \"start\": [[29]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"monoamine oxidase inhibitors\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hypertensive crisis or serotonin syndrome\"]], \"start\": [[192]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18294121_1 | According to the Naranjo adverse drug reaction probability scale, the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable (score of 6). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse drug reaction\"]], \"start\": [[123]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"temozolomide\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"temozolomide\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[148]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[158]], \"entity_id\": [\"T3\"], \"value\": true}}"
}
]
}
] |
10891991_4 | OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"women with epilepsy\"]], \"start\": [[96]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"women\"]], \"start\": [[96]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reproductive endocrine disorders\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
2857534_1 | Alprazolam-induced mania: two clinical cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Alprazolam\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Alprazolam\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"mania\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two clinical cases\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10679548_2 | Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"use of nitrofurantoin\"]], \"start\": [[66]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Bronchiolitis obliterans organising pneumonia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6692713_3 | To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[37]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
10660641_2 | A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"itraconazole (ITCZ)\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"Aspergillus flavus-induced chronic hypertrophic pachymeningitis\"]], \"start\": [[66]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12802933_1 | Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Severe autoimmune hemolytic anemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rituximab therapy\"]], \"start\": [[45]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"lymphoproliferative disorder\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient with a lymphoproliferative disorder\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11545487_6 | The renal consequences of indinavir-associated nephrotoxicity are uncertain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"indinavir\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"nephrotoxicity\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"uncertain\"]], \"start\": [[66]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
11834188_1 | BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[81]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[54]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"delated cutaneous reactions\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
24163322_7 | Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Bismuth subsalicylate 30 mL every 4 hours\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Bismuth subsalicylate\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"30 mL\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Freq\": {\"text\": [[\"every 4 hours\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"diarrhea\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19382926_6 | A drug interaction between the alpha(2)-adrenergic agonist medetomidine and lignocaine is suspected and highlights the potential for seizures following the subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[142]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[133]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation\"]], \"start\": [[156]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"lignocaine\"], [\"medetomidine\"]], \"start\": [[213], [230]], \"entity_id\": [\"T14\", \"T15\"]}, \"Route\": {\"text\": [[\"subcutaneous\"]], \"start\": [[156]], \"entity_id\": [\"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"under\"]], \"start\": [[224]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"medetomidine\"], [\"lignocaine\"]], \"start\": [[230], [213]], \"entity_id\": [\"T15\", \"T14\"]}}]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[119]], \"entity_id\": [\"T18\"], \"value\": true}}"
}
]
}
] |
7428724_2 | Oesophageal ulceration due to emepronium bromide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Oesophageal ulceration\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"emepronium bromide\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"emepronium bromide\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16432996_1 | Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Development\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"interferon alpha 2b and ribavirin\"]], \"start\": [[34]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"interferon alpha 2b\"], [\"ribavirin\"]], \"start\": [[34], [58]], \"entity_id\": [\"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[92]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[68]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"ribavirin\"], [\"interferon alpha 2b\"]], \"start\": [[58], [34]], \"entity_id\": [\"T13\", \"T12\"]}}]}}"
}
]
}
] |
9022114_2 | CONCLUSION: The findings in these two patients suggest that colchicine may delay corneal wound healing. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"delay\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"delay corneal wound healing\"]], \"start\": [[75]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"colchicine\"]], \"start\": [[60]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"corneal wound\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[71]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
12324937_3 | Gemcitabine-associated hemolytic-uremic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hemolytic-uremic syndrome\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9100429_1 | Case study: adverse response to clonidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"adverse response\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clonidine\"]], \"start\": [[32]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clonidine\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17163271_2 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[204]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"thrombosis of the central retinal vein\"]], \"start\": [[214]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[16]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"malignant hypertension\"]], \"start\": [[83]], \"entity_id\": [\"T4\"]}}, \"Treatment\": {\"text\": [[\"on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine\", \"undergone a renal transplantation as a result of malignant hypertension\"]], \"start\": [[119, 34]], \"entity_id\": [\"T1\"], \"Drug\": {\"text\": [[\"cyclosporin\"], [\"prednisone\"], [\"azathioprine\"]], \"start\": [[162], [175], [190]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}, \"Time_elapsed\": {\"text\": [[\"5 years\"]], \"start\": [[253]], \"entity_id\": [\"T2\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[186]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"cyclosporin\"], [\"prednisone\"], [\"azathioprine\"]], \"start\": [[162], [175], [190]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}}]}}"
}
]
}
] |
15300114_2 | In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"evident\"]], \"start\": [[109]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"topical bimatoprost\"]], \"start\": [[134]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bimatopros\"]], \"start\": [[142]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"three reported patients\"]], \"start\": [[15]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"alteration of eyelid appearance with deepening of the lid sulcus\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
16629074_1 | PURPOSE: To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"34 months after LASIK\"]], \"start\": [[82]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"34 months after\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"traumatic flap dehiscence and Enterobacter keratitis\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9220046_2 | CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lovastatin\", \"azithromycin\", \"clarithromycin\"]], \"start\": [[94, 109, 125]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lovastatin\"], [\"azithromycin\"], [\"clarithromycin\"]], \"start\": [[94], [109], [125]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[105]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"lovastatin\"], [\"azithromycin\"], [\"clarithromycin\"]], \"start\": [[94], [109], [125]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}}]}}"
}
]
}
] |
1509179_2 | Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exacerbating\"]], \"start\": [[92]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[74]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"maladaptive behaviors\"]], \"start\": [[105]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8835752_2 | Terbinafine-induced cholestatic liver disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Terbinafine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Terbinafine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"cholestatic liver disease.\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
21789791_2 | The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"apoptosis in several human cancers\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL\"]], \"start\": [[4]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Bortezomib\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19116715_2 | METHODS: A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[53]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"metastatic pancreatic adenocarcinoma,\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"HUS\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with metastatic pancreatic adenocarcinoma\"]], \"start\": [[81]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
2595431_3 | Their parkinsonism improved on discontinuation of metoclopramide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"discontinuation of metoclopramide therapy\"]], \"start\": [[31]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"parkinsonism\"]], \"start\": [[6]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"Their parkinsonism\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15304176_1 | Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Lichen planus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"hepatitis B vaccination\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hepatitis B vaccination\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18453852_4 | A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1-5. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"start\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"40 healthy volunteers\"]], \"start\": [[11]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"40\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"600 mg rifampicin once daily from days 1-5\"]], \"start\": [[60]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"600 mg\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"once daily\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9366852_1 | Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with antiphospholipid antibody syndrome\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Skin necrosis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"low-molecular weight heparin\"]], \"start\": [[27]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"antiphospholipid antibody syndrome\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"low-molecular weight heparin\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
20098333_1 | Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"anthracycline\", \"with ATRA\"]], \"start\": [[16, 67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"anthracycline\"], [\"ATRA\"]], \"start\": [[16], [72]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"anthracycline\"], [\"ATRA\"]], \"start\": [[16], [72]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"early chronic cardiomyopathy\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10395123_2 | Fixed drug eruption in hands caused by omeprazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"omeprazole\"]], \"start\": [[39]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"omeprazole\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Fixed drug eruption in hands\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12699871_1 | FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"before\"]], \"start\": [[117]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL)\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"FK506\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"12 days earlier\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"neurologic abnormalities began\"]], \"start\": [[124]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15224368_2 | Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[139]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"filgrastim\"]], \"start\": [[115]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"filgrastim\"]], \"start\": [[115]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Sweet's syndrome is an acute febrile neutrophilic dermatosis\", \"increased neutrophil proliferation and differentiation\"]], \"start\": [[0, 146]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12811715_1 | Although it would be expected that, like other type IA toxicities, diphenhydramine-induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[83]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[67]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"cardiotoxicity\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"responsive\"]], \"start\": [[115]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"hypertonic sodium bicarbonate\"]], \"start\": [[129]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"diphenhydramine-induced cardiotoxicity\"]], \"start\": [[67]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"hypertonic sodium bicarbonate\"]], \"start\": [[129]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"could\"]], \"start\": [[106]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
2016556_1 | We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"mild renal insufficiency\"]], \"start\": [[156]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"chronic nausea and an episode of confusion\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"a small, stable dose of oral morphine\"]], \"start\": [[100]], \"entity_id\": [\"T8\"], \"Dosage\": {\"text\": [[\"small, stable dose\"]], \"start\": [[102]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[124]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"morphine\"]], \"start\": [[129]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
2011096_1 | Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"children with leukemia\"]], \"start\": [[90]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[90]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Bulbar and pseudobulbar palsy\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"high-dose cytosine arabinoside\"]], \"start\": [[56]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[56]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"leukemia\"]], \"start\": [[104]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
1068531_2 | The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suggests\"]], \"start\": [[70]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide therapy\"]], \"start\": [[109]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[109]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"development of erythroid leukemia plus carcinoma\", \"mutagenic change\"]], \"start\": [[4, 79]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two men\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"men\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
25538343_3 | Administration of thiazide diuretics also has been the cause of hyponatremia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"thiazide diuretics\"]], \"start\": [[18]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"thiazide diuretics\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17122225_2 | Serotonin syndrome is a potentially lethal adverse drug reaction that may occur in patients taking proserotoninergic medications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"proserotoninergic medications\"]], \"start\": [[99]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"proserotoninergic\"]], \"start\": [[99]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"lethal\"]], \"start\": [[36]], \"entity_id\": [\"T11\"], \"value\": \"High\"}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[70]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
7519913_1 | However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[101]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"methimazole\"]], \"start\": [[75]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methimazole (MMI)\"]], \"start\": [[75]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"aplasia cutis congenita\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"questions\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
17896898_2 | An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD) was prescribed varenicline for smoking cessation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[76]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"18-year-old\"]], \"start\": [[3]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[15]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"attention-deficit-hyperactivity disorder (ADHD)\"]], \"start\": [[24]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"varenicline\"]], \"start\": [[87]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"varenicline\"]], \"start\": [[87]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"smoking cessation\"]], \"start\": [[103]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
3878320_2 | The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"unexplained abdominal pain or collapse\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"vasopressin\"]], \"start\": [[107]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[24]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
10357715_3 | The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after treatment\"]], \"start\": [[211]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcipotriol\"]], \"start\": [[232]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"calcipotriol\"]], \"start\": [[232]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"an allergic type of contact dermatitis\", \"an irritant type of reaction\"]], \"start\": [[139, 182]], \"entity_id\": [\"T3\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[105]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
1068531_1 | Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute erythroid leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide therapy\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"multiple myeloma\"]], \"start\": [[60]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[88]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
1642627_1 | A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[119]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"triazolam\"]], \"start\": [[109]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"triazolam\"]], \"start\": [[109]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"eating disorder\"]], \"start\": [[127]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15494638_2 | 5-fluorouracil (5-FU)-associated peripheral neuropathy is an uncommon event. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"peripheral neuropathy\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8908396_2 | Insulin-induced lipoatrophy in type I diabetes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Insulin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"type I diabetes\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Insulin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"lipoatrophy\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2327115_4 | This article describes a patient with suspected ciprofloxacin-induced interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[48]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"interstitial nephritis\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[38]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
10607332_1 | We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"3 cases of HIV-1 infected patients\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"symptomatic angiolipomas\"]], \"start\": [[61]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antiretroviral therapy including the protease inhibitor indinavir\"]], \"start\": [[109]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"HIV-1\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[165]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"shortly after\"]], \"start\": [[86]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
11093071_1 | Depressive symptoms disappeared after interferon therapy was stopped. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"interferon therapy\"]], \"start\": [[38]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Depressive symptoms\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12776809_2 | Coumarin is reported to elevate liver function tests (LFT) values. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Coumarin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Coumarin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"elevate liver function tests (LFT) values\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9723127_3 | Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Decreased plasma cortisol level\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"alprazolam\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"alprazolam\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"panic disorder\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8181372_1 | Severe diffuse interstitial pneumonitis induced by carmustine (BCNU). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"diffuse interstitial pneumonitis\"]], \"start\": [[7]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carmustine (BCNU)\"]], \"start\": [[51]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"carmustine\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
2394154_1 | Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Fever, pulmonary infiltrates, and pleural effusion\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"acyclovir therapy for herpes zoster ophthalmicus\"]], \"start\": [[61]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"herpes zoster ophthalmicus\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"acyclovir\"]], \"start\": [[61]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
1584367_2 | We propose a mechanism of vancomycin-induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE\"]], \"start\": [[45]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vancomycin\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"propose\"]], \"start\": [[3]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
6837655_3 | Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Within 3 weeks of beginning continuous daily isoniazid and rifampin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"pulmonary tuberculosis\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Time_elapsed\": {\"text\": [[\"Within 3 weeks of beginning\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[39]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"isoniazid\"], [\"rifampin\"]], \"start\": [[45], [59]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[55]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"isoniazid\"], [\"rifampin\"]], \"start\": [[45], [59]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8862924_5 | We report four cases of severe corneal ulceration in methamphetamine abusers. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"four cases\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"corneal ulceration\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methamphetamine\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methamphetamine\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[24]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
7375145_1 | Diagnosis: practolol induced sclerosing peritonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"practolol\"]], \"start\": [[11]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"practolol\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"sclerosing peritonitis\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19039026_2 | We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute interstitial nephritis\"]], \"start\": [[51]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[85]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Sunitinib\"]], \"start\": [[118]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"metastatic renal cell cancer\"]], \"start\": [[132]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Sunitinib\"]], \"start\": [[118]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12111771_3 | Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presentation\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Multiple pulmonary nodules\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"fludarabine\"]], \"start\": [[55]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19995222_1 | Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"schizophrenic patients\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"schizophrenic\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"tardive dyskinesia\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9701106_4 | Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[115]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"theophylline levels had increased to the toxic range\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"zafirlukast\"]], \"start\": [[137]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"zafirlukast\"]], \"start\": [[137]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"her\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"her\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
2738729_2 | Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Withdrawal emergent syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"an infant\"]], \"start\": [[32]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"maternal haloperidol therapy\"]], \"start\": [[58]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"haloperidol\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"maternal\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
812008_1 | Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"affected\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Diphenylhydantoin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Diphenylhydantoin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
15852680_1 | Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"bicalutamide and leuprorelin acetate\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bicalutamide\"], [\"leuprorelin acetate\"]], \"start\": [[62], [79]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"prostate cancer\"]], \"start\": [[122]], \"entity_id\": [\"T5\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"bicalutamide\"], [\"leuprorelin acetate\"]], \"start\": [[62], [79]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"interstitial pneumonitis\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3438585_1 | Gold-induced pneumonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[5]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Gold\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Gold\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12921505_4 | OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[78]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"significant hepatic and renal failure\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"argatroban\"]], \"start\": [[85]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"argatroban\"]], \"start\": [[85]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD)\"]], \"start\": [[99]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"heparin-induced thrombocytopenia (HIT)\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"significant\"]], \"start\": [[31]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[122]], \"entity_id\": [\"T1\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[114]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[114]], \"entity_id\": [\"T3\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[130]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
20378385_2 | Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"under\"]], \"start\": [[98]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"adalimumab\"]], \"start\": [[119]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[77]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[119]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Visceral leishmaniasis and macrophagic activation syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11215836_1 | He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"possible serotonin syndrome\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[115]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[115]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15878975_2 | Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Rh(0)(D) immune globulin intravenous\"]], \"start\": [[104]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Rh(0)(D) immune globulin\"]], \"start\": [[104]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[129]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"immune thrombocytopenic purpura\"]], \"start\": [[160]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
6484655_3 | Two patients had ampicillin-associated seizures. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[17]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15197722_1 | A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"restless legs symptoms\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha (IFN alpha) therapy\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16005413_9 | While many can benefit from coadministration of serotonergic antidepressants and opioids, it appears that some individuals are at increased risk for SS. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[140]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"SS\"]], \"start\": [[149]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"some individuals\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"coadministration of serotonergic antidepressants and opioids\"]], \"start\": [[28]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"serotonergic antidepressants\"], [\"opioids\"]], \"start\": [[48], [81]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministration\"]], \"start\": [[28]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"opioids\"], [\"serotonergic antidepressants\"]], \"start\": [[81], [48]], \"entity_id\": [\"T14\", \"T13\"]}}]}}"
}
]
}
] |
10099659_3 | Stomatitis, diarrhea, dermatitis, and myelosuppression are the main toxicities of 5-FU. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicities\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[82]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[82]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"diarrhea\", \"dermatitis\", \"myelosuppression\", \"Stomatitis\"]], \"start\": [[12, 22, 38, 0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
8921647_1 | After treatment with cimetidine, there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"was\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cimetidine\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cimetidine\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"a rapid deterioration with decreased oxygen saturation and arterial PO2 values\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11487721_3 | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"difficulty walking because of marked pain in the lower extremities and loss of proprioception\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"25 days after treatment with weekly taxol (80 mg/m(2)x3)\"]], \"start\": [[157]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"25 days\"]], \"start\": [[157]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"taxol\"]], \"start\": [[193]], \"entity_id\": [\"T14\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[186]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"80 mg/m(2)x3\"]], \"start\": [[200]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"advanced ovarian carcinoma\"]], \"start\": [[22]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"a case of advanced ovarian carcinoma\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"marked\"]], \"start\": [[93]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
11722307_1 | Agranulocytosis and granulocytopenia associated with quetiapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Agranulocytosis and granulocytopenia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"quetiapine\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16029707_3 | The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"multiple comedones and ruptured epidermoid cysts\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"imiquimod therapy\"]], \"start\": [[91]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2305654_1 | We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related ileus in patients treated with nimodipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[87]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcium antagonist\", \"nimodipine\"]], \"start\": [[67, 126]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"nimodipine\"]], \"start\": [[126]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"ileus\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12932249_1 | Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hyperpigmentation\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha therapy\"]], \"start\": [[25]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C virus infection\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
6142995_1 | Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Chlorambucil\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Chlorambucil\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"chromosome damage\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17705565_1 | Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"is\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
3195622_3 | Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
11706664_1 | Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exposed\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute asymptomatic hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a healthy normal volunteer\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"2 oral doses of amodiaquine and artesunate\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"2\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"amodiaquine\"], [\"artesunate\"]], \"start\": [[86], [102]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"artesunate\"], [\"amodiaquine\"]], \"start\": [[102], [86]], \"entity_id\": [\"T11\", \"T10\"]}}]}}"
}
]
}
] |
3753891_3 | The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient without coronary artery disease\"]], \"start\": [[180]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amsacrine\"]], \"start\": [[166]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"amsacrine\"]], \"start\": [[166]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"focal myocardial necrosis, presenting clinically as an acute myocardial infarction\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17420198_8 | Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"oxazepam\", \"Baclofen\"]], \"start\": [[13, 0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"right-sided hemiparesis contractures\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Baclofen\"], [\"oxazepam\"]], \"start\": [[0], [13]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"oxazepam\"], [\"Baclofen\"]], \"start\": [[13], [0]], \"entity_id\": [\"T11\", \"T10\"]}}]}}"
}
]
}
] |
11918514_2 | DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"implication of\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"mirtazapine\"]], \"start\": [[60]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"mirtazapine\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"SS\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16968538_3 | A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"oxaliplatin\"]], \"start\": [[18]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"oxaliplatin\"]], \"start\": [[18]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hemolytic and/or thrombocytopenic reactions\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
10410183_3 | CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"A 39-year-old white Jewish schizophrenic man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"39-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"white Jewish\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[55]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"an elevated serum CK concentration\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[72]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"schizophrenic\"]], \"start\": [[41]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[72]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
23624139_1 | Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Severe water intoxication\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin\"]], \"start\": [[39]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"non-steroidal anti-inflammatory drugs\"], [\"desmopressin\"]], \"start\": [[65], [107]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"non-steroidal anti-inflammatory drugs\"], [\"desmopressin\"]], \"start\": [[65], [107]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
17671884_3 | An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"red blood cell anemia\"]], \"start\": [[120]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"MMF with prednisone to treat pemphigus vulgaris\"]], \"start\": [[49]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"pemphigus vulgaris\"]], \"start\": [[78]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"MMF\"], [\"prednisone\"]], \"start\": [[49], [58]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[53]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"MMF\"], [\"prednisone\"]], \"start\": [[49], [58]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Speculated\": {\"text\": [[\"apparent\"]], \"start\": [[3]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
9256906_3 | Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recovered\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"cessation of suramin treatmen\"]], \"start\": [[124]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"suramin\"]], \"start\": [[137]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"cessation\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"our patient\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"his renal function gradually recovered\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |